Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen IncfiledCriticalAmgen Inc
Priority to MYPI9302249priorityCriticalpatent/MY119359A/en
Publication of MY119359ApublicationCriticalpatent/MY119359A/en
METHODS FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS,VIRAL INFECTIONS, AND OTHER CONDITIONS WITHOUT CAUSING SIGNIFICANT SIDE EFFECTS NORMALLY ASSOCIATED WITH INTERFERON THEREPY, INVOLVING ADMINISTERING TO A PATIENT IN NEED THEREOF A THERAPEUTICALLY EFFECTIVE AMOUNT OF CONSENSUS HUMAN LEUKOCYTE INTERFERON ARE DISCLOSED. ALSO DISCLOSED ARE PHARMACEUTICAL COMPOSITIONS OF CONSENSUS HUMAN LEUKOCYTE INTERFERON.(FIG. 1)
MYPI93022491993-10-271993-10-27Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
MY119359A
(en)
METHOD FOR TREATING VIRAL INFECTIONS WITH CONJUNCTIVE THERAPY WITH COMPOUNDS SIMILAR TO ACICLOVIR AND AN ANALOGUE OF 2'-VIRIL SUBSTITUTED NUCLEOSIDE.
Use of natural human alpha-interferon - in preparation of liquid medicaments for peroral administration for treating viral infections, neoplasia and immune diseases
Use of natural human alpha-interferon - in preparation of liquid medicaments for peroral administration for treating viral infections, neoplasia and immune diseases